{"id":2380,"date":"2025-01-10T11:32:46","date_gmt":"2025-01-10T08:32:46","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=2380"},"modified":"2025-03-27T16:49:38","modified_gmt":"2025-03-27T13:49:38","slug":"nippon-shinyaku-releases-first-clinical-trial-first-in-human-of-brogidirsen-ns-089-ncnp-02-for-the-treatment-of-duchenne","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/pt\/nippon-shinyaku-releases-first-clinical-trial-first-in-human-of-brogidirsen-ns-089-ncnp-02-for-the-treatment-of-duchenne\/","title":{"rendered":"Nippon Shinyaku lan\u00e7a o primeiro ensaio cl\u00ednico (primeiro em humanos) de Brogidirsen NS-089\/NCNP-02 para o tratamento de Duchenne"},"content":{"rendered":"<p class=\"wp-block-paragraph\">O Centro Nacional de Neurologia e Psiquiatria anunciou a publica\u00e7\u00e3o de um artigo de pesquisa no Cell Reports Medicine detalhando os resultados de um estudo iniciado pelo pesquisador para NS-089\/NCNP-02, conhecido como &quot;brogidirsen&quot;. Este tratamento inovador para distrofia muscular de Duchenne (DMD), desenvolvido em conjunto com a Nippon Shinyaku Co., Ltd., representa um avan\u00e7o significativo na terapia de salto do exon 44.<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>\u00cdndice<\/h2><nav><ul><li><a href=\"#key-findings-from-brogidirsen-include\">Resultados do ensaio cl\u00ednico Brogidirsen<\/a><\/li><li><a href=\"#what-is-brogidirsen\">O que \u00e9 Brogidirsen?<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"key-findings-from-brogidirsen-include\">Resultados do ensaio cl\u00ednico Brogidirsen<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Brogidirsen mostra restaura\u00e7\u00e3o de distrofina dependente da dose em ensaios com pacientes com DMD.<\/li>\n\n\n\n<li>Brogidirsen em altas doses atingiu 24.47% de n\u00edvel normal de distrofina na coorte DMD.<\/li>\n\n\n\n<li>O estudo demonstrou benef\u00edcios terap\u00eauticos com fun\u00e7\u00e3o motora est\u00e1vel ou melhorada e um perfil de seguran\u00e7a favor\u00e1vel sem eventos adversos graves.<\/li>\n\n\n\n<li>Biomarcadores s\u00e9ricos para DMD foram identificados, incluindo PADI2, TTN, MYOM2 e MYLPF.<\/li>\n\n\n\n<li>Brogidirsen demonstrou alta efici\u00eancia em c\u00e9lulas derivadas de urina de DMD, apoiando testes em humanos.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"what-is-brogidirsen\">O que \u00e9 Brogidirsen?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Brogidirsen (NS-089\/NCNP-02) \u00e9 um medicamento de \u00e1cido nucleico descoberto em conjunto pela Nippon Shinyaku e NCNP, e espera-se que seja um medicamento terap\u00eautico para pacientes com DMD com muta\u00e7\u00f5es do gene da distrofina pass\u00edveis de salto do exon 44.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Saber mais:<\/strong> <a href=\"https:\/\/dmdwarrior.com\/pt\/upcoming-exon-44-skipping-therapies-for-dmd\/\" data-type=\"post\" data-id=\"2811\">Pr\u00f3ximas terapias de salto do Exon 44 para o tratamento da distrofia muscular de Duchenne<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>The National Center of Neurology and Psychiatry is announced the publication of a research paper in Cell Reports Medicine detailing the results of an investigator-initiated trial for NS-089\/NCNP-02, known as &#8220;brogidirsen.&#8221; This innovative treatment for Duchenne muscular dystrophy (DMD), jointly developed with Nippon Shinyaku Co., Ltd., represents a significant advancement in exon 44 skipping therapy. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2383,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[138,137,141,127,77,142,136,139,140],"class_list":["post-2380","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-brogidirsen","tag-clinical-trial","tag-exon-44","tag-exon-44-skipping","tag-exon-skipping","tag-japan","tag-nippon-shinyaku","tag-ns-089","tag-ns-089-ncnp-02"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/2380","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/comments?post=2380"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/2380\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media\/2383"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media?parent=2380"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/categories?post=2380"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/tags?post=2380"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}